{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T20:44:46Z","timestamp":1771879486473,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,5,3]],"date-time":"2013-05-03T00:00:00Z","timestamp":1367539200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s40257-013-0023-y","type":"journal-article","created":{"date-parts":[[2013,5,2]],"date-time":"2013-05-02T14:05:20Z","timestamp":1367503520000},"page":"273-277","source":"Crossref","is-referenced-by-count":38,"title":["Pharmacotherapeutic Management of Actinic Keratosis: Focus on Newer Topical Agents"],"prefix":"10.1007","volume":"14","author":[{"given":"Aman","family":"Samrao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clay J.","family":"Cockerell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,3]]},"reference":[{"issue":"5","key":"23_CR1","first-page":"241","volume":"89","author":"B Berman","year":"2012","unstructured":"Berman B, Cohen DE, Amini S. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 1: overview and investigational topical agents. Cutis. 2012;89(5):241\u201350.","journal-title":"Cutis"},{"issue":"6","key":"23_CR2","first-page":"294","volume":"89","author":"B Berman","year":"2012","unstructured":"Berman B, Cohen DE, Amini S. What is the role of field-directed therapy in the treatment of actinic keratosis? Part 2: commonly used field-directed and lesion-directed therapies. Cutis. 2012;89(6):294\u2013301.","journal-title":"Cutis"},{"key":"23_CR3","first-page":"335","volume":"16","author":"PJ Quaedvlieg","year":"2006","unstructured":"Quaedvlieg PJ, Tirsi E, Thissen MR, et al. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol. 2006;16:335\u20139.","journal-title":"Eur J Dermatol"},{"issue":"suppl 2","key":"23_CR4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2133.2007.08271.x","volume":"157","author":"N Krawtchenko","year":"2007","unstructured":"Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157(suppl 2):34\u201340.","journal-title":"Br J Dermatol"},{"key":"23_CR5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archdermatol.2008.562","volume":"145","author":"B Yentzer","year":"2009","unstructured":"Yentzer B, Hick J, Williams L, et al. Adherence to a topical regimen of 5-fluorouracil 0.5% cream for the treatment of actinic keratosis. Arch Dermatol. 2009;145:203\u20135.","journal-title":"Arch Dermatol"},{"key":"23_CR6","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archderm.140.7.813","volume":"140","author":"J Jorizzo","year":"2004","unstructured":"Jorizzo J, Weiss J, Furst K, et al. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol. 2004;140:813\u20136.","journal-title":"Arch Dermatol"},{"issue":"suppl 2","key":"23_CR7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2133.2007.08272.x","volume":"157","author":"E Stockfleth","year":"2007","unstructured":"Stockfleth E, Sterry W, Carey-Yard M, et al. Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. Br J Dermatol. 2007;157(suppl 2):41\u20136.","journal-title":"Br J Dermatol"},{"issue":"4","key":"23_CR8","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2009.07.004","volume":"62","author":"N Swanson","year":"2010","unstructured":"Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of\u00a0actinic\u00a0keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62(4):582\u201390.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"23_CR9","first-page":"1432","volume":"10","author":"P Foley","year":"2011","unstructured":"Foley P, Merlin K, Cumming S, Campbell J, et al. A comparison of cryotherapy and imiquimod for treatment of actinic keratoses: lesion clearance, safety, and skin quality outcomes. J Drugs Dermatol. 2011;10(12):1432\u20138.","journal-title":"J Drugs Dermatol"},{"key":"23_CR10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2310\/7750.2007.00033","volume":"11","author":"JK Tan","year":"2007","unstructured":"Tan JK, Thomas DR, Poulin Y, et al. Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses. J Cutan Med Surg. 2007;11:195\u2013201.","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"23_CR11","first-page":"600","volume":"11","author":"GM Martin","year":"2012","unstructured":"Martin GM, Stockfleth E. Diclofenac sodium 3% gel for the management of actinic keratosis: 10\u00a0+\u00a0years of cumulative evidence of efficacy and safety. J Drugs Dermatol. 2012;11(5):600\u20138.","journal-title":"J Drugs Dermatol"},{"key":"23_CR12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2133.2006.07692.x","volume":"156","author":"D Berker de","year":"2007","unstructured":"de Berker D, McGregor JM, Hughes BR. British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses [published correction in Br J Dermatol. 2008;158:873]. Br J Dermatol. 2007;156:222\u201330.","journal-title":"Br J Dermatol"},{"issue":"1","key":"23_CR13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2230.2008.02783.x","volume":"34","author":"M Mastrolonardo","year":"2009","unstructured":"Mastrolonardo M. Topical diclofenac 3% gel plus cryotherapy for treatment of multiple and recurrent actinic keratoses. Clin Exp Dermatol. 2009;34(1):33\u20135.","journal-title":"Clin Exp Dermatol"},{"key":"23_CR14","first-page":"156","volume":"5","author":"SR Smith","year":"2006","unstructured":"Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol. 2006;5:156\u20139.","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"23_CR15","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1158\/0008-5472.CAN-03-2837","volume":"64","author":"SM Ogbourne","year":"2004","unstructured":"Ogbourne SM, Suhrbier A, Jones B, et al. Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004;64(8):2833\u20139.","journal-title":"Cancer Res"},{"issue":"1","key":"23_CR16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1440-0960.2008.00497.x","volume":"50","author":"G Siller","year":"2009","unstructured":"Siller G, Gebauer K, Welburn P, et al. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol. 2009;50(1):16\u201322.","journal-title":"Australas J Dermatol"},{"issue":"5","key":"23_CR17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1365-2133.2011.10387.x","volume":"165","author":"E Stockfleth","year":"2011","unstructured":"Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose\u00a05-fluorouracil\u00a0in combination with\u00a0salicylic acid\u00a0as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol. 2011;165(5):1101\u20138.","journal-title":"Br J Dermatol"},{"issue":"1","key":"23_CR18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2133.2008.08615.x","volume":"159","author":"RM Szeimies","year":"2008","unstructured":"Szeimies RM, Bichel J, Ortonne JP, et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol. 2008;159(1):205\u201310.","journal-title":"Br J Dermatol"},{"key":"23_CR19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/11311170-000000000-00000","volume":"11","author":"E Campione","year":"2010","unstructured":"Campione E, Diluvio L, Patern\u00f2 EJ, et al. Topical treatment of actinic keratoses with piroxicam 1% gel: a preliminary open-label study utilizing a new clinical score. Am J Clin Dermatol. 2010;11:45\u201350.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"23_CR20","first-page":"128","volume":"7","author":"C Huyke","year":"2009","unstructured":"Huyke C, Reuter J, R\u00f6dig M, et al. Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study. J Dtsch Dermatol Ges. 2009;7(2):128\u201333.","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-013-0023-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-013-0023-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-013-0023-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:28:30Z","timestamp":1559503710000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-013-0023-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,3]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["23"],"URL":"https:\/\/doi.org\/10.1007\/s40257-013-0023-y","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,3]]}}}